Abstract:Changcheng Tao, 1, &ast Fan Wu, 1, &ast Hongwei Wang, 1, &ast Liming Wang, 1 Yue Liu, 1 Anke Wu, 1 Linlin Zheng, 1 Yaru Wang, 1 Bo Chen, 2 Weiqi Rong, 1 Jianxiong Wu 1 1 Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China; 2 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jianxiong Wu; Weiqi Rong, Email ; Objective: Although surgical resection is one of the most effective way to treat liver cancer, its efficacy and safety in treatment of centrally located hepatocellular carcinoma (HCC) remains elusive. Therefore, it is very important to find a comprehensive treatment mode, such as radical resection combined with neoadjuvant radiotherapy (neoRT). Methods: The centrally located HCC patients who underwent radical resection from July 2015 to April 2021 were enrolled. According to whether the neoRT was implemented or not, these patients were allocated into neoadjuvant radiotherapy combined with liver resection (neoRT+LR) and liver resection alone (LR) group. The research method used propensity-score analysis and Cox proportional-hazards regression models. We generated an E-value to assess the sensitivity to unmeasured confounding. This study is a real-world, retrospective study based on phase II clinical trial. Results: A total of 168 patients were enrolled, including 38 patients treating with neoRT+LR and 130 patients with LR. The 1-, 3-, 5-year disease free survival (DFS) rates were 74%, 55% and 39% in the neoRT+LR group, and 44%, 28%, and 24% in the LR group, respectively. Neoadjuvant radiotherapy was an independent prognostic factor for postoperative recurrence ([HR]0.42, 95% CI [0.25, 0.69]). There was significant association between neoRT+LR and longer disease-free survival (Match, [HR] 0.43, 95% CI [0.24, 0.76]; GenMatch, [HR] 0.32, 95% CI [0.23, 0.43]; Adjusted for propensity score, [HR] 0.41, 95% CI [0.23, 0.73]; Inverse probability weighting, [HR] 0.38, 95% CI [0.22, 0.65], respectively). DFS before and after matching analysis was statistically different in two groups ( p -value=0.005, p -value=0.0024, respectively). Neoadjuvant radiotherapy can significantly reduce the postoperative early recurrence ( p -value < 0.05). E-value analysis suggested robustness to unmeasured confounding. Conclusion: Liver resection combined with neoadjuvant radiotherapy was effective and safe for treatment of centrally located HCC patients, which improved the prognosis of patients and reduced the incidence of early recurrence. Keywords: centrally located hepatocellular carcinoma, neoadjuvant radiotherapy, radical resection, recurrence Malignant tumor of liver is one of the most common tumor in the world. An estimated 19.3 million new cancer cases and 10 million cancer-related deaths occurred globally in 2020. Liver cancer represents 4.7% of all new malignancies and 8.3% of cancer deaths in the world. 1 Primary liver cancer (PLC) is a lethal disease associated with high morbidity and poor prognosis and always a prerequisite question to be solved in clinical applications. 2 Hepatocellular carcinoma (HCC) accounts for approximately 90% of all cases of PLC. 3 The treatment strategies for liver cancer include surgical resection, liver transplantation, radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE), of which, surgical resection is the most important and effective treatment. 4 However, 70% patients develop a tumor relapse in 5 years after surgical resection. 5 Centrally located HCC is a tumor located at the bifurcation of the portal vein, the confluence of the three main hepatic veins, the inferior vena cava or within 1 centimeter (cm) of the posterior inferior vena cava trunk, usually located in Couinaud segments I, IV, V, VIII, or at the junction of the central segments. 6,7 Due to its proximity to important blood vessels and bile ducts, the treatment of centrally located HCC still faces big challenges in the clinic, which is raising concerns over the world. It is reported that the recurrence rate of centrally located HCC after five years is more than 90%, and the five-year DFS is 15–30%. 8 Narrower resec -Abstract Truncated-

Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma: A Nonrandomized Controlled Trial.

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Clinical Benefits of Neoadjuvant Radiotherapy on the Postoperative Recurrence of Centrally Located Hepatocellular Carcinoma: A Real-World Evidence Based on Phase II Clinical Trial

Phase 2 Study of Adjuvant Radiotherapy Following Narrow‐Margin Hepatectomy in Patients With HCC

Adjuvant Radiotherapy in Centrally Located Hepatocellular Carcinomas after Hepatectomy with Narrow Margin (<1 Cm): a Prospective Randomized Study.

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.

Adjuvant radiotherapy after curative resection of hepatocellular carcinoma with narrow margin (≤1 cm): A phase 2, multicenter, randomized controlled trial.

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Long-Term Outcome of Centrally Located Hepatocellular Carcinomas Treated by Radical Resection Combined With Intraoperative Electron Radiotherapy (IOERT)

Comparing the Efficacy and Safety of Local-Regional Treatments for Hepatocellular Carcinoma with Portal/hepatic Vein Tumor Thrombosis in China: a Network Meta-Analysis of Randomized Controlled Trials.

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma

Stereotactic Body Radiation Therapy in Patients with Centrally Located Hepatocellular Carcinoma: A Retrospective, Single-Arm, Multi-Center Study

Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.

Long-term outcome of adjuvant radiotherapy upon postoperative relapse of centrally located hepatocellular carcinoma: a real-world study

Three-Dimensional Conformal Radiotherapy (3DCRT) Combined with Transcatheter Arterial Chemoembolization (TACE) for Inoperable or Unresectable Hepatocellular Carcinoma (HCC): Clinical Phase I/II Trial

Phase I Trial of Radiation Dose Escalation in Patients with Locally Advanced Hepatocellular Carcinoma: an Interim Report

Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: A 10-year real-world evidence

Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review

Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC

Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.